These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 16515307

  • 1. [Long-term prevention of MS: effectiveness alone is not enough].
    Haas J.
    Krankenpfl J; 2005; 43(7-10):237. PubMed ID: 16515307
    [No Abstract] [Full Text] [Related]

  • 2. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
    Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Oluf A.
    Lakartidningen; 2005; 104(22):1684-8. PubMed ID: 17601317
    [No Abstract] [Full Text] [Related]

  • 3. [Ensuring the long-term effectiveness of MS treatment].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16515305
    [No Abstract] [Full Text] [Related]

  • 4. The gap between effect of drugs and effectiveness of treatments.
    Sorensen PS.
    J Neurol Sci; 2007 Aug 15; 259(1-2):128-32. PubMed ID: 17362994
    [Abstract] [Full Text] [Related]

  • 5. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B, Tremlett H.
    Neurology; 2005 Mar 08; 64(5):778-9. PubMed ID: 15753408
    [No Abstract] [Full Text] [Related]

  • 6. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 7. Interferon-beta for multiple sclerosis: Long-term benefits?
    Rudick RA, Cutter G.
    Ann Neurol; 2007 Apr 26; 61(4):283-5. PubMed ID: 17444503
    [No Abstract] [Full Text] [Related]

  • 8. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov 26; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 9. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
    Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S.
    Adv Ther; 2011 Jan 26; 28(1):51-61. PubMed ID: 21153000
    [Abstract] [Full Text] [Related]

  • 10. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A.
    Neuropediatrics; 2006 Aug 26; 37(4):257-60. PubMed ID: 17177154
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic management of multiple sclerosis.
    Blasier MG.
    Urol Nurs; 2008 Jun 26; 28(3):217-9. PubMed ID: 18605517
    [No Abstract] [Full Text] [Related]

  • 12. Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.
    Carmona O, Masuet C, Alía P, Moral E, Alonso-Magdalena L, Casado V, Martín-Ozaeta G, Arbizu T.
    Eur Neurol; 2011 Jun 26; 65(3):132-7. PubMed ID: 21325856
    [Abstract] [Full Text] [Related]

  • 13. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J, Lublin FD.
    Adv Neurol; 2006 Jun 26; 98():257-71. PubMed ID: 16400838
    [No Abstract] [Full Text] [Related]

  • 14. A practical guide to pediatric multiple sclerosis.
    Huppke P, Gärtner J.
    Neuropediatrics; 2010 Aug 26; 41(4):157-62. PubMed ID: 21086219
    [Abstract] [Full Text] [Related]

  • 15. A new treatment era in multiple sclerosis: clinical applications of new concepts.
    Edan G, Leray E.
    J Neurol Sci; 2011 Jul 15; 306(1-2):170-2. PubMed ID: 20951999
    [Abstract] [Full Text] [Related]

  • 16. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Carroll WM.
    Mult Scler; 2009 Aug 15; 15(8):951-8. PubMed ID: 19465446
    [Abstract] [Full Text] [Related]

  • 17. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T.
    Eur Neurol; 2008 Aug 15; 60(6):279-84. PubMed ID: 18824855
    [Abstract] [Full Text] [Related]

  • 18. Control of multiple sclerosis relapses with immunomodulating agents.
    Johnson KP.
    J Neurol Sci; 2007 May 15; 256 Suppl 1():S23-8. PubMed ID: 17350652
    [Abstract] [Full Text] [Related]

  • 19. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N, Théorêt G.
    Can J Neurosci Nurs; 2008 May 15; 30(4):18-25. PubMed ID: 19146204
    [Abstract] [Full Text] [Related]

  • 20. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O.
    Ann Neurol; 2008 Jan 15; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.